

# New Medicines Decisions for May 2025

## donanemab (Kisunla®)

| SMC Drug ID | Conditions   | Decision   | Date published on SMC Website | Date of decision / Expected date of decision |
|-------------|--|--|-------------------------------|--|
| SMC2687     | for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers. | Not routinely available as not recommended for use in NHS Scotland | 12/05/2025                    | 23/04/2025                                   |

### Other Decision Specified :

Web Link : <https://scottishmedicines.org.uk/media/9140/donanemab-kisunla-final-april-2025-for-website.pdf>

## sodium thiosulfate (Pedmarqsi®)

| SMC Drug ID | Conditions   | Decision   | Date published on SMC Website | Date of decision / Expected date of decision |
|-------------|--|--|-------------------------------|--|
| SMC2730     | for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours. | Routinely available from a specialist centre in another health board | 12/05/2025                    | 17/09/2025                                   |

### Other Decision Specified :

Web Link : <https://scottishmedicines.org.uk/media/9137/sodium-thiosulfate-pedmarqsi-final-april-2025-for-website.pdf>

# New Medicines Decisions for May 2025

## erdafitinib (Balversa®)

| SMC Drug ID   | Conditions   | Decision  | Date published on SMC Website | Date of decision / Expected date of decision |
|---|--|---|-------------------------------|--|
| SMC2738   | as monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. | Available in line with local or regional guidance | 12/05/2025                    | 17/09/2025                                   |
| <b>Other Decision Specified :</b>   |  |   |                               |  |
| <b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9142/erdafitinib-balversa-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9142/erdafitinib-balversa-final-april-2025-for-website.pdf</a> |  |   |                               |  |

## fruquintinib (Fruzaqla®)

| SMC Drug ID   | Conditions   | Decision   | Date published on SMC Website | Date of decision / Expected date of decision |
|---|--|--|-------------------------------|--|
| SMC2748   | treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy. | Not routinely available as not recommended for use in NHS Scotland | 12/05/2025                    | 10/08/2025                                   |
| <b>Other Decision Specified :</b>   |  |  |                               |  |
| <b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9143/fruquintinib-fruzaqla-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9143/fruquintinib-fruzaqla-final-april-2025-for-website.pdf</a> |  |  |                               |  |

# New Medicines Decisions for May 2025

## mepolizumab (Nucala®)

| SMC Drug ID   | Conditions   | Decision  | Date published on SMC Website | Date of decision / Expected date of decision |
|---|--|---|-------------------------------|--|
| SMC2765   | <p>as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.</p> <p>SMC restriction: patients who have eosinophils of at least 150 cells per microlitre (0.15 x 10<sup>9</sup>/L) at initiation of treatment and have had at least three asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.</p> | Not routinely available as the ADTC is waiting for further advice from local clinical experts | 12/05/2025                    | 27/02/2026                                   |
| <b>Other Decision Specified :</b>   |  |   |                               |  |
| <b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9135/mepolizumab-nucala-abb-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9135/mepolizumab-nucala-abb-final-april-2025-for-website.pdf</a> |  |   |                               |  |

## elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya®)

| SMC Drug ID   | Conditions   | Decision   | Date published on SMC Website | Date of decision / Expected date of decision |
|---|--|--|-------------------------------|--|
| SMC2809   | treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in paediatric patients aged from 2 years and with body weight at least 14 kg to less than 25 kg. | Not routinely available as not recommended for use in NHS Scotland | 12/05/2025                    | 23/04/2025                                   |
| <b>Other Decision Specified :</b> Non-submission  |  |  |                               |  |
| <b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9141/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya-non-sub-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9141/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya-non-sub-final-april-2025-for-website.pdf</a> |  |  |                               |  |

# New Medicines Decisions for May 2025

| sarilumab (Kevzara®)  |   |  |                               |  |
|---|---|--|-------------------------------|--|
| SMC Drug ID   | Conditions  | Decision   | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2810   | treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper. | Not routinely available as not recommended for use in NHS Scotland | 12/05/2025                    | 23/04/2025                                   |
| <b>Other Decision Specified :</b> Non-submission  |   |  |                               |  |
| <b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9136/sarilumab-kevzara-non-sub-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9136/sarilumab-kevzara-non-sub-final-april-2025-for-website.pdf</a> |   |  |                               |  |